SCHEMBL18270945

SCHEMBL18270945

Cc1cccc2c1C(=O)N([C@H]1CCCCNC1=O)C2=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 14/20 0.65
CRBN Q96SW2 14/20 0.65
IKZF3 Q9UKT9 2/20 0.50
TNF P01375 1/20 0.50
IL1B P01584 1/20 0.50
TBXA2R P21731 1/20 0.50
IKZF1 Q13422 1/20 0.50
HTR2B P41595 2/20 0.44
TMEM97 Q5BJF2 2/20 0.44
HTR3E A5X5Y0 1/20 0.44
HTR3B O95264 1/20 0.44
HTR3A P46098 1/20 0.44
HTR3D Q70Z44 1/20 0.44
HTR3C Q8WXA8 1/20 0.44
ALDH1A1 P00352 1/20 0.43
CHRM2 P08172 1/20 0.43
OPRM1 P35372 1/20 0.43
CYP1A2 P05177 1/20 0.43
TSHR P16473 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22845577 0.96 DDB1 (0.67) DDB1CRBNIKZF3TNFIL1B
SCHEMBL18270883 0.90 DDB1 (0.63) DDB1CRBNIKZF3TNFIL1B
SCHEMBL18263931 0.90 DDB1 (0.63) DDB1CRBNIKZF3TNFIL1B
SCHEMBL3125601 0.86 CRBN (0.55) DDB1CRBNIKZF3TNFIL1B
SCHEMBL18263933 0.86 CRBN (0.55) DDB1CRBNIKZF3TNFIL1B
SCHEMBL20766657 0.86 DDB1 (0.64) DDB1CRBNIKZF3TNFIL1B
SCHEMBL19612069 0.86 DDB1 (0.51) DDB1CRBNIKZF3TNFIL1B
SCHEMBL20766660 0.86 DDB1 (0.64) DDB1CRBNIKZF3TNFIL1B
SCHEMBL19612072 0.86 DDB1 (0.51) DDB1CRBNIKZF3TNFIL1B
SCHEMBL19585360 0.86 DDB1 (0.64) DDB1CRBNIKZF3TNFIL1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298004-B1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX INC (US) 2021-01-06 EP disclosed
US-10669260-B2 Compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2020-06-02 US disclosed
US-10562917-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2020-02-18 US disclosed
US-20190276474-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2019-09-12 US disclosed
US-9938302-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2018-04-10 US disclosed
US-20180065952-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2018-03-08 US disclosed
US-20170334932-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2017-11-23 US disclosed
US-20170333443-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2017-11-23 US disclosed
WO-2017201069-A1 OXOINDOLINE DERIVATIVES AS PROTEIN FUNCTION MODULATORS BIOTHERYX, INC. (US) 2017-11-23 WO disclosed
US-9822098-B2 Compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2017-11-21 US disclosed
US-20160362397-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2016-12-15 US disclosed
WO-2016191178-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. (US) 2016-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180065952-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, APC DDB1 2732/4885CRBN 548/4885IKZF3 1/4885
US-10669260-B2 Compounds targeting proteins, compositions, methods, and uses thereof IKZF3, IKZF1, APC DDB1 2732/4885CRBN 548/4885IKZF3 1/4885
US-10562917-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof IKZF3, IKZF1, CKS1B DDB1 2485/4885CRBN 176/4885IKZF3 1/4885
US-20160362397-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, APC DDB1 2732/4885CRBN 548/4885IKZF3 1/4885
US-20170333443-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, CKS1B DDB1 2485/4885CRBN 176/4885IKZF3 1/4885
US-20170334932-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, CKS1B DDB1 2485/4885CRBN 176/4885IKZF3 1/4885
US-20190276474-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, CKS1B DDB1 2485/4885CRBN 176/4885IKZF3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.